Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age 55 to 85 years;~2. should have a mild-to-moderate AD diagnosis (MMSE 10-26 inclusive);~3. should have evidence of elevated cortical amyloid by PET using florbetapir F18 (Amyvid) \[i.e. a positive scan\], assessed qualitatively according to the Amyvid product label.~4. if on anti-dementia treatment should be on stable treatment for at least 2 months (i.e. cholinesterase inhibitor and/or Memantine or Axona);~5. stable on all other medications for at least 30 days prior to screen;~6. should be fluent in English;~7. should be physically able to participate by medical history, clinical exam and tests;~8. should have a study partner to accompany them to scheduled visits.~Exclusion Criteria:~1. clinically relevant arrhythmias;~2. a resting pulse less than 50;~3. active cancer other than non-melanoma skin cancers;~4. use of another investigatory drug within 2 months of screening;~5. significant stroke or head trauma by history or MRI;~6. contraindication for having a MRI;~7. diagnostic and Statistical Manual of Mental Disorders-IV criteria for a current major psychiatric disorder;~8. sensitivity to yeast or yeast products;~9. impaired kidney function as measured by a Glomerular Filtration Rate less than 60 milliliters/min;~10. preexisting fluid retention, pulmonary infiltrates, or congestive heart failure;~11. history of moderate-to-severe lung disease;~12. history of moderate-to-severe liver disease;~13. pregnant women, or any women who feel they are likely to become pregnant during the study;~14. prisoners.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Sagramostim (Leukine) (Type: EXPERIMENTAL): 5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
- Control Group (Type: PLACEBO_COMPARATOR): Saline -- placebo comparator. Given as a subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).